Finance

Lists
NATCOPHARM:NSE
Natco Pharma
800,00 INR
+1,34%
(+10,60) 1D
12-окт., 15:30:01 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for NATCOPHARM...
Open
789,40 INR
High
804,75 INR
Low
789,40 INR
Mkt. cap
156,93 млд
Avg. vol.
436,28 миң
Volume
501,24 миң
Dividend
0,56%
Quarterly dividend
1,12 INR
Ex-dividend date
2026-ж., 20-авг.
P/E ratio
12,62
52-wk high
1 216,89 INR
52-wk low
785,65 INR
EPS
63,37 INR
Shares outstanding
182,26 млн
No. of employees
4 миң
Open
789,40 INR
High
804,75 INR
Low
789,40 INR
Mkt. cap
156,93 млд
Avg. vol.
436,28 миң
Volume
501,24 миң
Dividend
0,56%
Quarterly dividend
1,12 INR
Ex-dividend date
2026-ж., 20-авг.
P/E ratio
12,62
52-wk high
1 216,89 INR
52-wk low
785,65 INR
EPS
63,37 INR
Shares outstanding
182,26 млн
No. of employees
4 миң
News stories
From web sources and news partners
Profile
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs at affordable prices. Wikipedia
About Natco Pharma
CEORajeev Nannapaneni
Employees4,43 миң
Founded1981
HeadquartersБанжара Хилс, Телангана, Индия
SectorPharmaceutical industry
Last report
2026-ж., 14-авг.
Fiscal period
Q1 2027
11,53 INR / 8,86 INR
+30,06%beat
Revenue / Est. (INR)
7,35 млд / 7,96 млд
-7,66%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
13,63 млд
6,47 млд
7,43 млд
7,35 млд
Cost of goods sold
1,70 млд
1,33 млд
1,99 млд
1,48 млд
Cost of revenue
1,70 млд
1,33 млд
1,99 млд
1,48 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,00 млд
1,59 млд
1,63 млд
1,79 млд
Operating expense
6,66 млд
4,02 млд
4,38 млд
4,48 млд
Total operating expenses
8,36 млд
5,35 млд
6,37 млд
5,96 млд
Operating income
5,27 млд
1,12 млд
1,06 млд
1,39 млд
Other non operating income
1,00 млд
581,00 млн
-2,11 млд
592,00 млн
EBT including unusual items
6,14 млд
1,72 млд
1,80 млд
2,70 млд
EBT excluding unusual items
6,14 млд
1,72 млд
2,02 млд
2,70 млд
Income tax expense
958,00 млн
207,00 млн
-892,00 млн
634,00 млн
Effective tax rate
15,61%
12,03%
-49,61%
23,49%
Other operating expenses
4,14 млд
1,96 млд
2,23 млд
2,22 млд
Net income
5,18 млд
1,52 млд
2,68 млд
2,06 млд
Net profit margin
38,03%
23,40%
36,08%
28,09%
Earnings per share
28,94
8,46
14,96
11,53
Interest and investment income
-
-
2,33 млд
-
Interest expense
-131,00 млн
-95,00 млн
-
-130,00 млн
Net interest expenses
-131,00 млн
-95,00 млн
2,33 млд
-130,00 млн
Depreciation and amortization charges
524,00 млн
462,00 млн
504,00 млн
471,00 млн
EBITDA
5,82 млд
1,57 млд
1,55 млд
1,91 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору